Outcome of the Meeting of Board of Directors held on Thursday, 07th August, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 1.0 pts less than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Directors of Genpharmasec Limited approved the unaudited standalone and consolidated financial results for the quarter ended 30 June 2025. On a standalone basis, revenue from operations surged to ₹1,211.32 lakhs from ₹530.29 lakhs in Q1 FY25, a growth of roughly 128% year-on-year. Standalone profit after tax jumped to ₹155.92 lakhs from ₹58.87 lakhs (~165% YoY), while EPS rose to ₹0.03 from ₹0.01. On a consolidated basis, revenue from operations rose to ₹1,204.32 lakhs and profit after tax climbed to ₹121.52 lakhs from ₹28.68 lakhs (~324% YoY). The auditor's limited review report was unqualified. The company noted that it gained controlling interest in Derren Healthcare Pvt Ltd as of 25 July 2025, which is expected to contribute to future consolidation.
Strong top-line and bottom-line growth driven by the pharmaceutical segment should be viewed positively by shareholders, though the consolidation of recently acquired Derren Healthcare will be a key thing to watch in coming quarters. The lack of any auditor qualifications and the absence of segment-level losses in core pharma (Lab Testing subsidiary Clinigenome is loss-making) are encouraging signs for the stock.